Racecadotril
Trade name: redotil
Racecadotril, also known as acetorphan, is an antidiarrheal medication which acts as a peripheral enkephalinase inhibitor. Unlike other opioid medications used to treat diarrhea, which reduce intestinal motility, racecadotril has an antisecretory effect — it reduces the secretion of water and electrolytes into the intestine. It is available in France and other European countries as well as most of South America and some South East Asian countries, but not in the United States. It is sold under the tradename Hidrasec, among others. Thiorphan is the active metabolite of racecadotril, which exerts the bulk of its inhibitory actions on enkephalinases. — Wikipedia
Clinical trial activity
12 trials · 14 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2007 (NCT01153854)
Timeline
Indications
Approved for
Mechanism of action
- NeprilysinINHIBITOR
MME inhibitor
Chemistry & pharmacology
SMILES
O=C(O)CNC(=O)C(CS)Cc1ccccc1- Mol. weight
- 253.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRacecadotril ↗
- ChEMBLCHEMBL2103772 ↗
- ChEMBLCHEMBL1516410 ↗
- ChEMBLCHEMBL10247 ↗
Also known as
- acetorphan
- acetorphan
- acetorphan, (r)-isomer
- acetorphan, (s)-isomer
- cadotril
- ecadotril
- ecadotril
- ecadotril
- ecadotril
- ecadotril
- ecadotril
- glycine, n-(2-((acetylthio)methyl)-1-oxo-3-phenylpropyl)-, phenylmethyl ester, (+-)-
- hidrasec
- hidrasec
- n-(3-acetylmercapto-2-benzylpropanoyl)glycine benzyl ester
- racecadotril
- racecadotril
- racecadotril
- racecadotril
- racecadotril
- racecadotril
- racecadotril
- redotil
- retorphan
- sinorphan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06297174 | Phase 1 | Aug 26, 2024 | Mahidol University, Pharma Nueva |
| NCT06529497 | Phase 1/Phase 2 (Phase 2) | Aug 2, 2024 | Liaquat University of Medical & Health Sciences |
| NCT05600062 | N/A | Jan 16, 2023 | Medical Research Council, University of London |
| NCT04885049 | N/A | Sep 1, 2021 | Shaheed Zulfiqar Ali Bhutto Medical University |
| NCT03473561 | Phase 3 | Aug 25, 2018 | Abbott |
| NCT05216822 | Phase 1 | Jun 1, 2018 | Assiut University |
| NCT03463512 | Phase 3 | Mar 29, 2018 | Abbott |
| NCT01948011 | Phase 1 | Sep 1, 2013 | Bioprojet, Eurofins |
| NCT01476683 | Phase 1 | Dec 1, 2011 | McNeil |
| NCT01577043 | Phase 4 | Sep 1, 2011 | Centro Pediatrico Albina de Patino |
| NCT01302093 | Phase 1 | Jan 1, 2011 | McNeil |
| NCT01153854 | Phase 3 | Jan 1, 2007 | Ferrer Laboratories, Government of Mexico |
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 2 | 2 | 1 | 2018 |
| McNeil | For profit | 2 | 2 | 1 | 2011 |
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Bioprojet | For profit | 1 | 1 | 1 | 2013 |
| Centro Pediatrico Albina de Patino | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Eurofins | For profit | 1 | 0 | 1 | 2013 |
| Ferrer Laboratories | For profit | 1 | 0 | 1 | 2007 |
| Government of Mexico | Government | 1 | 1 | 1 | 2007 |
| Liaquat University of Medical & Health Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Mahidol University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Medical Research Council | Government | 1 | 0 | 1 | 2023 |
| Pharma Nueva | For profit | 1 | 1 | 1 | 2024 |
| Shaheed Zulfiqar Ali Bhutto Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2023 |